EMA Authorised: Kerendia (Finerenone) — Bayer AG

View source ↗

Summary

The European Medicines Agency authorised Kerendia (finerenone) from Bayer AG for the treatment of chronic kidney disease in adults with type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Kerendia (finerenone)

Snippet

Status: Authorised. Therapeutic area: Renal Insufficiency, Chronic;Diabetes Mellitus, Type 2. MAH: Bayer AG. Decision date: 16/01/2026